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Abstract. Induction of drug metabolizing enzymes, such as the cytochromes P450 (CYP) is known to
cause drug-drug interactions due to increased elimination of co-administered drugs. This increased
elimination may lead to signiﬁcant reduction or complete loss of efﬁcacy of the co-administered drug.
Due to the signiﬁcance of such drug interactions, many pharmaceutical companies employ screening and
characterization models which predict CYP enzyme induction to avoid or attenuate the potential for drug
interactions with new drug candidates. The most common mechanism of CYP induction is transcriptional
gene activation. Activation is mediated by nuclear receptors, such as AhR, CAR, and PXR that function
as transcription factors. Early high throughput screening models utilize these nuclear hormone receptors
in ligand binding or cell-based transactivation/reporter assays. In addition, immortalized hepatocyte cell
lines can be used to assess enzyme induction of speciﬁc drug metabolizing enzymes. Cultured primary
human hepatocytes, the best established in vitro model for predicting enzyme induction and most
accepted by regulatory agencies, is the predominant assay used to evaluate induction of a wide variety of
drug metabolizing enzymes. These in vitro models are able to appropriately predict enzyme induction in
patients when compared to clinical drug-drug interactions. Finally, transgenic animal models and the
cynomolgus monkey have also been shown to recapitulate human enzyme induction and may be
appropriate in vivo animal models for predicting human drug interactions.
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INTRODUCTION
Enzyme induction is the process of creating more
enzyme than is normally present in a biological system. As
early as 1954, the ﬁrst report of enzyme induction appeared in
a manuscript by Brown, et al. who described the enzyme
inducing effects of various diets given to rodents; this was
followed some time later by the ﬁrst review on microsomal
enzyme induction in 1967 (1,2). The increase in enzyme
activity, in effect an increase in intrinsic metabolic clearance,
is reﬂected by increased hepatic clearance of drugs metabo-
lized by the induced enzyme. Pharmacokinetically, the drugs
affected by enzyme induction generally demonstrate reduced
AUC, Cmax, and half-life as a reﬂection of increased
clearance. For example, the antidiabetic drug rosiglitazone
(CYP2C8 substrate) when administered with the inducing
agent rifampicin has been reported to cause 65%, 31%, and
62% decreases in AUC, Cmax, and half-life of rosiglitazone,
respectively (3). A more dramatic example is illustrated by
the interaction between midazolam (CYP3A4 substrate) and
the herbal antidepressant St. John’s Wort (CYP3A4 inducer)
where the midazolam AUC and Cmax decreased by 79% and
65%, respectively (4). These pharmacokinetic changes have
signiﬁcant pharmacological consequences because increased
metabolism reduces the duration and pharmacological effect
of co-adminstered drugs. For example, the induction of
CYP3A4 results in reduced ethinylestradiol levels from oral
contraceptives that can lead to unexpected pregnancies and
reduced cyclosporine concentrations in transplant patients
can lead to organ rejection (both drugs are predominately
metabolized by CYP3A4). In general, the decrease in AUC
ranges from 15–98%, depending on the potency of the
inducing agent, the fraction of drug metabolized, and the
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ABBREVIATIONS: AhR, aromatic hydrocarbon receptor; AUC,
area under the plasma concentration-time curve; CAR, constitutive
androstane receptor; CITCO, (6-(4-chlorophenyl)imidazo[2,1-β]
[1,3]thiazole-5-carbaldehyde O-(3,4-dichlorbenzyl)oxime); Cmax,
maximum plasma concentration; Css, drug concentration at steady
state; CYP, cytochrome P450; EC50, concentration of an agonist
that produces 50% of the maximal response; DBD, DNA binding
domain; DDI, drug-drug interaction; Emax, maximal response
(effect); hSC, human stem cells; IC50, concentration of drug that
produces 50% inhibition; LDB, ligand binding domain; PXR,
pregnane X receptor; Pgp, P-glycoprotein; STs, sulfo-transferases;
SXR, steroid and xenobiotic receptor; UGTs, glucuronosyl-
transferasesoverall elimination of a drug via the induced pathway, as
illustrated in Table I with several well known human probe
substrates for each CYP.
In addition to the examples where one drug (perpetra-
tor) causes the induction and a second drug’s( v i c t i m )
pharmacokinetics are altered, there exists a situation where
a single drug acts as both inducer and affected drug, called
autoinduction. Carbamazepine and artemisinin are examples
of CYP3A4 and CYP2B6 substrates and inducers, respective-
ly, that are known to exhibit autoinduction (5,6). Auto-
induction is a phenomenon that can occur anytime a drug
induces an enzyme which is also predominately involved in its
own metabolic clearance. Therefore, when understanding the
overall liability of an enzyme inducer, a complete under-
standing of the major pathways and enzymes involved in
elimination are important to assess autoinduction.
Drug-drug interactions (DDIs) are occurring with in-
creasing frequency due to the rise in multiple prescriptions
taken by individual patients. The average older adult uses
between two and six prescription medications, and between
one and three over-the-counter medications regularly (7).
Due to the increase in DDIs, the need to develop compounds
lacking the ability to induce metabolizing enzymes has
become a signiﬁcant concern and exercise in developing
new drugs. Most pharmaceutical companies have imple-
mented several layers of screening and characterization to
assess enzyme induction. In early drug discovery, large
numbers of compounds are screened by means of high
throughput assays to eliminate compounds with enzyme
induction potential or reduce the liability by selecting
compounds with lower potencies for the inductive effect.
During preclinical development, characterization in more
complex human systems helps to further deﬁne the induction
potential of a compound. Ultimately, the effect or lack of
effect of a potential enzyme inducer is evaluated in human
volunteers/patients with well characterized CYP probe sub-
strates (Table I) where the actual magnitude of pharmacoki-
netic change is measured. Therefore, the aim of this review is
to describe the assays most commonly employed to assess
enzyme induction in the pharmaceutical industry. The focus
will be on CYP enzymes induced in the liver, as this is the
main emphasis for pharmaceutical companies and encom-
passes the most signiﬁcant drug-drug interactions, in partic-
ular, CYP3A4 interactions.
NUCLEAR HORMONE
RECEPTORS—TRANSCRIPTION FACTORS
There are two general mechanisms by which enzyme
induction occurs: (1) stabilization of the mRNA or enzyme
(e.g., CYP2E1) (8) and (2) increased gene transcription. The
most common mechanism of CYP enzyme induction is
transcriptional gene activation. For drug metabolizing
enzymes, transcriptional activation is mediated by nuclear
receptors that function as transcription factors, such as AhR
(aromatic hydrocarbon receptor), CAR (constitutive andros-
tane receptor), and PXR (pregnane X receptor or SXR-
steroid X receptor) (9–14). The general concept for nuclear
receptor signaling is that in the absence of a ligand (drug), the
nuclear receptor is associated with co-repressor complexes,
conferring a basal level of transcription. Ligand (drug)
binding to the ligand binding domain (LBD) of the nuclear
receptors induces conformational changes that lead to the
release of co-repressors and recruitment of co-activators.
Recruitment of co-activators and a dimerization partner
(retinoid X receptor, RXR, for CAR/PXR and the AhR
nuclear translocator, ARNT, for AhR) lead to chromatin
remodeling and subsequent transcriptional activation. Regu-
lation of gene transcription is achieved through binding of the
nuclear receptor DNA binding domain (DBD) to respective
DNA response elements present in the promoter region of
target genes (drug metabolizing enzymes) (14,15). Figure 1
illustrates the components of both the nuclear receptor and
target gene (promoter and gene or reporter gene). Table II
lists several nuclear receptors and their target genes (CYP,
glucuronyl- and sulfo-transferases: UGTand ST, respectively). It
should be noted that the LBDs of many nuclear receptors are
different between various animal species and human (14).
Table I. Percent AUC Changes in Humans with Probe Drugs for
Various CYP Enzymes
CYP Drug Probes
Percent AUC
Decrease
CYP1A Theophylline 15–66%
CYP2B6 Efavirenz 20–30%
CYP2C8 Rosiglitazone/Repaglinide 32–80%
CYP2C9 Warfarin/Tolbutamide 16–63%
CYP2C19 Omeprazole 25–49%
CYP3A4 Midazolam 20–98%
Data taken from the University of Washington Metabolism and
TransportDrugInteractiondatabase.http://www.druginteractioninfo.org/
Fig. 1. Illustration of domainsofnuclearreceptors(a) and structure of a gene construct with promoter region
and target gene or transfection vector for a transactivation assay with promoter region and reporter gene (b)
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of enzyme induction can be misleading and are generally not
employed to assess the potential induction effect in humans.
PXR-derived nuclear hormone receptor models are the
most common high throughput assays to evaluate enzyme
induction due to the simplicity of ligand-based activation and
importance of target genes, such as CYP3A4, CYP2B6, and
CYP2Cs in drug interactions. Ligand binding assays generally
consist of genetically expressed and isolated receptors incu-
bated with test compound and a radiolabeled ligand. Com-
petition of the radiolabeled ligand with test compound is
measured and an IC50 determined (16). These assays are
reasonably straightforward to conduct, however their simplic-
ity can also be a deﬁcit in some situations. Often, only a
portion of the receptor is expressed (LBD), not the full length
receptor, and there is no cell membrane to act as a potential
barrier to drug access (or allow for drug accumulation). Cell-
based PXR transactivation assays illustrate a more complex
nuclear hormone receptor assay. The PXR transactivation
model is comprised of two expression vectors: (1) full length
human PXR and (2) a variation of the CYP3A4 5′-promoter
region coupled to a reporter gene (17,18) both expressed in
an appropriate cell line. Similar transactivation assays also
exist for the Ah receptor (19). Here, increased luminescence
is typically measured as an indication of enzyme induction
potential and EC50 and Emax values are determined. In
general, there is a good correlation between EC50 and IC50
values in PXR transactivation and binding assays, respective-
ly (16). However, there are examples where signiﬁcant
binding to the PXR receptor does not lead to transactivation
or enzyme induction. These unique situations can be caused
by PXR antagonists or ligands which do not elicit the
appropriate displacement of co-repressors or recruitment of
co-activators [e.g., docetaxel and paclitaxel (20)]. Many
companies have replaced the PXR binding assay with a
PXR transactivation assay which has equal throughput, less
false positives, no need for radiolabeled reagents, and
improved correlation to human drug–drug interactions (18).
Interpretation of hPXR data can be as simple as rank
ordering of EC50 values and comparison to known CYP3A4
inducers (rifampicin) providing useful information on poten-
cy. However, many hPXR transactivation plots yield partial
response plots (partial agonists) which make EC50 determi-
nations less useful and incorporation of Emax values along
with EC50’s necessary. More accurate predictions of drug
interactions incorporate therapeutic drug concentrations,
such as therapeutic total drug concentrations (Cmax or Css)
along with transactivation data. Combining values and
obtaining a ratio of Cmax/EC50 can be predictive in assessing
the likelihood of a drug interaction much like the approach
used for drug inhibition assessments. More complex calcu-
lations include several parameters, such as EC50, Emax, and
Cmax and have been used to assess induction effects for
multiple induction models (transactivation, immortalized
hepatocytes, and primary hepatocytes) (18,21,22).
Equation 1 (where Ceff is the efﬁcacious drug concentration):
Effect ¼ Ceff   Emax ðÞ = Ceff þ EC50 ðÞð 1Þ
Another approach compares the percent transactivation
at the therapeutic drug concentration (Cmax) to a known
enzyme inducer. Using this approach, it has been demon-
strated that compounds causing >40% transactivation at a
therapeutic drug concentrations are predicted to “likely”
have drug interactions, compounds with percent transactiva-
tion between 15–40% “may” elicit drug interactions, and
those with percent transactivation <15% are “not anticipat-
ed” to cause drug interactions (18). Figure 2 illustrates how
three different efﬁcacious drug concentrations can affect the
prediction of CYP3A4 induction based on PXR transactiva-
tion data. Concentrations A, B and C (low, moderate, and
high effective concentrations) would be predicted to not elicit
a PXR response, may elicit a response, and would be
expected to elicit a response, respectively. In another
example, hyperforin has an EC50=0.04 μM in the hPXR
transactivation assay, an approximate efﬁcacious plasma
concentration of 0.3 μM, and a percent transactivation of
80% at the efﬁcacious concentration. In contrast, pioglitazone
has an EC50=31 μM in the hPXR transactivation assay, an
efﬁcacious plasma concentration of ∼3.8 μM, and a percent
Table II. Nuclear Receptors and Their Target Genes
Nuclear Receptor Target Genes
AhR CYP1A1, CYP1A2 CYP1B1, CYP2S1, UGT1A1, UGT1A6, SULT2B
CAR CYP2A6, CYP2B6, CYP2C9, CYP2C19, CYP3A4, UGT1A1, UGT2B1, SULT2A1
PXR CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP3A4, CYP3A5, CYP3A7 UGT1A1,
UGT1A3, UGT1A4, UGT1A6, UGT1A9, SULT2A1
Compiled from references: (75–80)
Fig. 2. Example of how efﬁcacious drug concentration can affect the
predictability of induction potential from a plot of PXR trans-
activation vs. drug concentration. A, B, and C represent multiple
efﬁcacious concentrations for a hypothetical drug
393 CYP450 Enzyme Inductiontransactivation of 10% at the efﬁcacious concentration.
Combined, the parameters of these two drugs would predict
that hyperforin would cause CYP3A4 drug interactions while
pioglitazone should not and this is borne out in actual clinical
drug interactions (18).
Unfortunately, few examples exist in the literature of
successful elimination of PXR-mediated CYP3A4 induction
by use of the PXR transactivation assay (23,24). This may be
due to the relatively new application of these assays in the
pharmaceutical industry and the proprietary nature of the
work. What has been learned from in silico modeling of PXR
ligands indicate that disruption of key interactions (hydrogen
bond acceptor and hydrophobic interactions) between ligand
and PXR ligand binding domain are essential to attenuate or
eliminate PXR-mediated induction (23).
The mechanisms of CAR and AhR-mediated gene
transcription differs somewhat from that of PXR. Both
CAR and AhR can be activated by direct ligand binding as
described above, however they can also be activated by
ligand binding independent mechanisms. Translocation of
CAR to the nucleus can be initiated by direct agonist binding
to the receptor or through a partially elucidated ligand-
independent mechanism involving kinases which dephosphor-
ylate CAR. Phenobarbital is an example of a drug that does
not bind to CAR yet causes nuclear translocation and
transcriptional activation of the target gene, CYP2B6 (12).
Similarly, the inactive AhR resides in the cytoplasm and can
be activated upon ligand binding or via protein tyrosine
kinases. Omeprazole mediated induction of CYP1A has been
shown to proceed through this kinase-mediated pathway (25)
although this premise has come under debate (26).
One disadvantage of nuclear hormone receptor based
assays is that each assay only evaluates one receptor-
mediated process at a time. For example, hPXR trans-
activation assays will predict induction of PXR target genes;
however activation of the same target genes can occur
through other nuclear hormone receptors, such as CAR
which would not be represented in a PXR assay. This nuclear
receptor cross-talk with target genes are best evaluated in
more complex cell based models (hepatocytes) where multi-
ple nuclear hormone receptors can work in concert and
provide a cumulative effect on target genes (14).
IMMORTALIZED HEPATOCYTES
Immortalized cells have the ability to grow and divide
indeﬁnitely and can occur naturally, from tumoral origin, or
through oncogenic immortalization of primary cells. The
advantages of using immortalized cell lines over transfected cell
systems or primary hepatocytes for enzyme induction studies
include:(1)potentialtosimultaneouslycapturemultiplenuclear
hormone receptor-mediated pathways; (2) easy access and
availability; 3) the ability to propagate (i.e., continual supply);
and (4) a more consistent response to inducers. Although
immortalized cell lines are used extensively to study various
mechanisms of enzyme induction or as the basis for speciﬁc
nuclear receptor assays (e.g., hPXR transactivation), those will
not bedescribed here.The following discussionwilldescribecell
lines that have an innate ability to respond directly to enzyme
inducers and produce an induction response, as measured by
mRNA expression or enzyme activity.
The most utilized cell system in the pharmaceutical
industry is the non-tumorigenic immortalized hepatic cell line
Fa2N-4. Fa2N-4 cells demonstrate inducible CYP1A1/2,
CYP3A4, CYP2C9, UGT1A and MDR1 mRNA expression
and increases in enzyme activity (CYP1A2, CYP2C9 and
CYP3A4) when treated with prototypical inducers. The
responses to rifampicin and beta-naphthoﬂavone were shown
to be within the range observed for primary human hepato-
cytes (21,27). This cell line appears promising for discovery-
stage induction studies keeping in mind some limitations. For
example, the native or basal enzyme activities are low and
therefore it is difﬁcult to measure enzyme activities in vehicle
treated samples without sensitive analytical methods. Due to
this, mRNA is a more routine endpoint when using this cell
line. In a recent publication, 24 compounds that have been
previously evaluated for induction in primary human hep-
atocytes were assessed for induction in Fa2N-4 cells using
mRNA analysis as the marker for induction (21). The data
indicated a majority of the compounds showed comparable
induction between primary hepatocytes and Fa2N-4 cells as
assessed by using Eq. 1 and developing a Relative Induction
Score for each compound. One exception was troglitazone
which is a very potent inducer both in the clinic and in
primary hepatocytes (28), yet gave a very moderate induction
response with the Fa2N-4 cell line, indicating that perhaps all
the nuclear receptor pathways are not present or fully
functional in Fa2N-4 cells. Indeed, Lyon, et. al., have shown
that the Fa2N-4 cells have very low levels of CAR and do not
respond to the CAR-speciﬁc agonist CITCO (29).
Other cell lines of note, albeit not employed extensively
in the pharmaceutical industry, are HepG2, HepaRG, and
BC2. These human hepatoma cell lines have been used for
induction studies, as some of the CYP enzymes are inducible,
even though the expression levels of Phase I and Phase II
drug metabolism enzymes are signiﬁcantly lower than those
in human primary hepatocytes. HepG2 and HepaRG cells
have been shown to respond, to varying degrees, to CYP1A1/
2 and 3A4 inducers (30–32) and BC2 cells have been reported
to respond to CYP1A inducers (33). While these cell lines can
be used for preliminary studies, they do not maintain all of
the phenotypic characteristics of human hepatocytes, such as
enzyme or receptor function or expression, and their use may
result in erroneous conclusions. Nonetheless, they appear to
be gaining more attention as an earlier alternative to primary
hepatocyte experiments for assessing CYP1A and 3A induc-
tion potential in drug discovery.
PRIMARY HUMAN HEPATOCYTES
Cultured primary human hepatocytes are the most
accepted (industry, academia, regulatory) in vitro system for
assessing the potential for drug candidates to induce human
CYP expression (34). Human hepatocytes are a cellular
system comprised of human receptors, co-activators and
repressors, target genes and promoters, as well as human
drug metabolizing enzymes capable of biotransforming drugs.
These properties are analogous to the liver and are essential
to effectively model the inducibility of drug candidates and
their metabolites. Primary human hepatocyte culture systems
have been shown to effectively model human in vivo
induction responses and are recognized by the FDA as an
394 Sinz, Wallace and Sahieffective tool for assessing induction potential (35,36). The
enzyme induction data from in vitro methods are known to
correlate well with clinical observations, provided the in vitro
experiments are performed at pharmacologically relevant
concentrations of drug (37). When hepatocytes are cultured
using appropriate conditions which facilitate liver-like cell
morphology and expression of liver-speciﬁc proteins, CYP
enzymes are effectively induced in vitro analogous to the in
vivo situation in terms of the magnitude and speciﬁcity of
induction (37,38). For example, omeprazole is an effective in
vitro inducer of human CYP1A2 (37,39), but the EC50 of
omeprazole induction is much larger than the typical expo-
sure in humans treated for gastric ulcers, thus it rarely causes
signiﬁcant clinical drug interactions because the concentration
of omeprazole required to induce CYP1A2 exceeds the
concentrations achieved in vivo (37,40,41). In addition to
CYP enzymes, numerous studies have been reported using
primary hepatocyte culture systems to assess induction of a
variety of gene targets from Phase II enzymes and trans-
porters (42–45).
The FDA draft guidance on drug interactions states “A
drug that induces a drug-metabolizing enzyme can increase
the rate of metabolic clearance of a co-administered drug that
is a substrate of the induced pathway. A potential conse-
quence of this type of drug-drug interaction is sub-therapeutic
blood concentrations” (36). The draft guidance recommends
analysis of catalytic activity of the major drug metabolizing
enzymes CYP1A2 and CYP3A4 in freshly isolated or
attachable cryopreserved hepatocyte cultures. Since co-induc-
tion of CYP2C, CYP2B and P-gp occurs with CYP3A,
negative results in vitro with CYP3A may also eliminate the
need to address interactions by these CYPs and P-gp.
Samples should be analyzed from at least three individual
donors, treated with the test compound, vehicle and positive
controls (known prototypical inducers) for 2–3 days. Each
hepatocyte donor preparation is deemed acceptable if the
recommended positive control elicits a greater than 2-fold
increase in enzyme activity of the probe substrate. A
minimum of three test compound concentrations, based on
the expected human plasma drug levels are suggested, one of
which should be an order of magnitude greater than this
concentration. In the absence of knowledge of human plasma
levels, concentrations ranging over at least two orders of
magnitude should be studied. The FDA draft guidance allows
for enzymatic analysis to be conducted in microsomes
prepared from hepatocytes or in situ, using media-based
assays and CYP-speciﬁc probe substrates, where the metab-
olite formed can be attributed to one major CYP enzyme.
The data from cultured hepatocyte experiments can take
several forms, such as, fold increase, percent increase or EC50
values. More recently, percent increase and EC50 values have
been found to be more predictive than fold increase. For
example, a drug that produces an increase in probe drug
enzyme activity that is equal to or more than 40% of the
enzyme activity of positive control inducer will be regarded as
an enzyme inducer. EC50 values are often used to rank order
test compounds based on inducer potency or used in
calculations such as Eq. 1. The interpretation and prediction
of in vivo induction (DDI) from human hepatocytes are very
similar to those employed in nuclear receptor transactivation
assays. When results from in vitro studies demonstrate
signiﬁcant induction by test compound vs. induction with the
positive control, the potential for in vivo induction should be
assessed in clinical DDI studies.
Additional methods to determine enzyme induction
currently being evaluated are quantitation of CYP protein
by Western immunoblotting and reverse transcriptase-poly-
merase chain reaction (RT-PCR) to measure mRNA levels
(RNA expression is particularly useful when both enzyme
induction and inhibition are occurring). However, measure-
ment of enzyme activities from incubations in primary human
hepatocytes is still considered the most reliable method to
determine induction potential of a compound.
While fresh human hepatocytes are the standard for
evaluating in vitro induction of CYP enzymes, attachable
cryopreserved hepatocytes can also be used and data using
these are accepted by the FDA. The drug metabolizing
enzymes remain inducible after cryopreservation, and due to
the signiﬁcant variation in activities of drug metabolizing
enzymes between individual human livers, certain lots of
cryopreserved cells can generate results essentially indistin-
guishable from freshly isolated cells (35,46). mRNA, protein
expression and activities of CYP1A2, 2B6, 2C9, 2E1 and 3A4
in cryopreserved hepatocytes are inducible by prototypical
inducers (47), as is the activity of various UDP-glucuronosyl-
transferases, carboxylesterases, and sulfotransferases (48,49).
The advantage cryopreserved cells offer over fresh isolates is
that experiments can be planned ahead and are not depen-
dent on the sporadic availability of fresh primary hepatocytes.
Unfortunately, the commercial supply of attachable cryopre-
served human hepatocyte preparations is somewhat limited,
as a majority of cryopreserved hepatocyte preparations lose
the ability to attach to extracellular matrices in culture.
CLINICAL DRUG INTERACTION STUDIES
Clinical DDI studies are performed to measure the
changes in pharmacokinetic parameters of a test compound
by concomitant drug administration. The speciﬁc objective of
DDI studies is to provide pharmacokinetic recommendations
for dose or interval adjustments of the drug itself, or the drugs
with which it may be prescribed, and to determine if
additional therapeutic monitoring is required (36). DDI
studies are usually required in Phase II or III, however they
can be planned at any time during drug development if results
from in vitro data suggest there is a potential for DDIs. The
general design of an in vivo DDI study is to compare the
concentrations of test drug with and without a comedicant
(36). A cross-over design, in healthy volunteers (both male
and female), is usually appropriate in order to reduce
variability. In general, the same subjects are dosed initially
with a probe substrate (assess baseline pharmacokinetics),
followed by ∼2 weeks of dosing with the drug candidate, and
ﬁnally a dose of the probe substrate. The study design should
be such that both drug and comedicant are dosed to
exposures that are clinically relevant; the route of adminis-
tration is the same as planned for clinical use, and given at the
highest clinical dose possible using the shortest dosing
interval. This should maximize the possibility of a DDI being
uncovered. When appropriate, exclusion of dietary supple-
ments including herbal products, over the counter medica-
tions, alcohol, fruit juices or other foods (including
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metabolizing enzymes and transporters should be imple-
mented to avoid variation in study results. In these experi-
ments, complete plasma concentration time proﬁles of the
probe drug are sampled. Often plasma concentrations of drug
candidate (inducer) are also measured to ensure appropriate
exposure to inducing agent. Endpoints measured include all
relevant pharmacokinetic parameters of parent drug and
relevant metabolites. Primary endpoints measured are expo-
sure measures such as AUC and Cmax, as well as other
pharmacokinetic parameters (clearance, volume of distribu-
tion, tmax, and half-life). No-effect-boundaries (where changes
in measurement of systemic exposure have no clinical
meaning) should be deﬁned based on clinical relevance. Data
evaluation in these studies should include noncompartmental
pharmacokinetic analysis, descriptive statistics of the phar-
macokinetic parameters, calculation of inter- and intra-
individual variability, and calculation of the 90% conﬁdence
intervals for AUC and Cmax ratios between treatments. A
signiﬁcant outcome of these studies would be alteration of the
pharmacokinetics by concomitant drug administration and
the subsequent dosing recommendation and labeling of
contraindications.
If the drug is being studied as a potential inducer of CYP
enzymes, the choice of probe or substrate depends on which
CYP enzymes are affected by the inducer. Common probe
substrates include midazolam, theophylline, repaglinide, war-
farin, and omeprazole for CYP3A4, 1A2, 2C8, 2C9 and 2C19,
respectively. If initial studies with these substrates show
potential for DDI then additional studies with other probes
may be performed if there is a possibility of co-administra-
tion. Table III contains a list of substrates/probes used and
known inducers for each CYP. For example, the most
sensitive probe for CYP3A4 activity is oral midazolam, a
commonly used hypnotic since the 1980s (50). Most of the
elimination of this drug is through metabolism by CYP3A4/5
(51,52). Lack of CYP3A4 induction with co-administration of
midazolam following multiple doses of investigational drug
indicates that the drug is not a CYP3A4 inducer.
Administering a cocktail of different substrates of CYP
enzymes is also conducted in clinical investigations of enzyme
induction albeit more common in academic than industrial
settings. Choice of substrates is important as they need to be
CYP speciﬁc with no interactions between any of the
substrates in the cocktail. A recent study by Asimus et al.
(53), investigated the effect of the antimalarial drug artemi-
sinin and its derivatives on the major human CYP enzymes.
Asimus et al. designed a six drug cocktail study consisting of
caffeine, coumarin, mephenytoin, metoprolol, chlorzoxazone
and midazolam to assess CYP1A2, 2A6, 2C19, 2D6, 2E1 and
3A4 activity, respectively. The investigators found that
artemisinin and/or one or more of its derivatives caused
induction of CYP3A4, 2C19 and CYP1A2 using this cocktail
approach. Hence, such a DDI will need to be considered
when selecting appropriate therapies for malaria and combi-
nation treatments.
FUTURE MODELS
There are multiple in silico, in vitro and in vivo models of
induction being developed with varying degrees of success.
All appear promising; however additional evaluation and a
greater understanding of how best to employ these models
are still necessary.
In Silico
In silico simulations and structure-activity relationships
(SAR) are useful tools to help eliminate potentially problem-
atic chemotypes early in drug development. Successful
induction models combine the crystal structure of nuclear
receptor proteins with in silico structural biology (54). For
example, the PXR crystal structure and protein indicate that
the LBD is hydrophobic with several key polar residues and
Table III. Commonly Used In Vivo Probes for Clinical Studies and CYP Inducers
CYP Enzyme Substrate/Probe Inducer
1A2 Theophylline, caffeine, acetaminophen, aromatic
amines, phenacetin
Cigarette smoke, omeprazole
charbroiled meats, cruciferous vegetables
2A6 Coumarin, butadiene, nicotine Barbiturates
2B6 Efavirenz Rifampin
2C8 Repaglinide, rosiglitazone Rifampin
2C9 S-warfarin, tolbutamide, phenytoin, NSAIDs Rifampin, barbiturates,
2C19 Omeprazole, esoprazole, lansoprazole, pantoprazole,
citalopram, diazepam, hexobarbital, imipramine,
proguanil, propanolol
Rifampin, barbiturates
2D6 Antidepressants, neuroleptics, beta-blockers,
antiarrhytmics, codeine, etylmorphine, desipramine,
dextromethorphan, atomoxetine, nicoteine
None identiﬁed
2E1 Chlorzoxazone, acetaminophen, alcohols, caffeine,
dapsone, enﬂurane, theophylline
Ethanol, isoniazid
3A4/3A5 Midazolam, buspirone, felodipine, lovastatin, eletriptan,
sildenaﬁl, simavastatin, triazolam, acetaminophen,
carbamezapine, cyclosporin, digitoxin, diazepam, erythromycin,
ﬂuoxetine, nifedipine, quinidine, saquinavir, steroids
(e.g. cortisol), terfenadine, verapamil, warfarin
Rifampin, carbamazepine, dexamethasone,
phenytoin, troleandomycin
Compiled from references: (36,81)
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(55,56). Evaluation of AhR ligand structures indicates that
substrates are planar lipophilic molecules about 6.8×13.7 Å in
dimension (57). Ligands for hCAR identiﬁed by pharmacophore
modeling were relatively planar structures with one hydrogen
bond acceptor and three hydrophobic features (58). Potent
ligands for PXR are similar to CAR ligands, in that at least one
hydrogen bond acceptor feature and one or more hydrophobic
interactions are necessary for good binding and activation (23).
Merely docking the compound in the protein structure
may not always sufﬁce, as the large ligand-binding domain of
hPXR accommodates ligands of all sizes. Ligands of all
shapes and sizes have been shown to alter the protein
structure after binding indicative of an ‘induced-ﬁt’ mecha-
nism which ultimately is difﬁcult to model (54). Complicating
factors in ligand binding pharmacophore models are adjacent
sites on the nuclear receptor which can be involved in
conformational changes that affect binding. For example,
Ekins and Wang have reported that agonists and antagonists
bind to distinct regions on PXR and that the effects of
ketoconazole were mediated through binding to the AF-2
region of PXR and not the LBD (Fig. 2)( 59,60).
Stem Cells
Human stem cells (hSC) could theoretically provide an
unlimited source of hepatocytes once culture conditions are
optimized to enable differentiation. These stem cells can
differentiate into hepatocyte-like cells, albeit often with
limited drug metabolizing capability. Due to the random
nature in obtaining primary human hepatocytes and the
variable results from different donors, multiple laboratories
are currently working on developing a hepatocyte-like cell
line from hSC. Some examples of cells derived from hSC are
HLC cells which exhibit hepatocyte morphology and limited
CYP metabolism (61). Two hepatocyte-like cell lines (SA002
and SA167) derived from hSC demonstrate inducible
CYP1A1 and CYP3A4/7 mRNA and immunoreactive pro-
tein, as well as CYP2C8/9/19 mRNA but no catalytic activity
(62). The NeoHep cells developed from terminally differen-
tiated peripheral blood monocytes, exhibit hepatocyte-like
morphology, expression of hepatocyte markers, limited drug
metabolism (CYP1A and UGT) and CYP3A induction (63).
Phenobarbital-inducible CYP mRNA expression and enzy-
matic activity (64) and inducible CYP1A activity (65) have
been reported in other hSC-derived cell lines. While these
studies provide hope for hSC-derived hepatocytes being
developed for metabolism studies in the future, thus far, no
stem-cell derived cell lines (differentiated hepatocytes) are
employed in enzyme induction screening or characterization.
Transgenic/Chimeric Animals
Humanized nuclear receptor transgenic mice, knock out
mice and chimeric mice with human transplanted hepato-
cytes, are useful tools for assessing enzyme regulation by drug
candidates. These in vivo models provide an advantage over
previous in vitro models, as the systems are dynamic, with
drug absorption, distribution, metabolism, and elimination
occurring concurrently. Drug candidates can be administered
over several days at doses/exposures equivalent to those
expected in human plasma to enable improved assessments of
human induction potential. For example, dose-dependent
increases in CYP3A11 mRNA were observed with increasing
concentrations of rifampicin in hPXR transgenic mice (66).
The limitation of the transgenic/knock out systems are that
only one or two genes are “humanized” and the cross-talk
between nuclear receptors/enzymes/transporters may be
compromised as the human and mouse systems may or may
not be working in a similar fashion. Humanized chimeric mice
Fig. 3. A representation of in vitro and in vivo induction models in order of decreasing throughput and
increasing reliability/predictability (open squares: current models; open circles: future models). Assays such
as the transactivation and immortalized hepatocyte assays are extremely high throughput, however they
lack the complexity of human hepatocytes which represent the multitude of transcription factors/receptors
and their interactions and dynamic drug exposure which occurs in patients
397 CYP450 Enzyme Inductionwere developed by injecting human hepatocytes into SCID
mice (80% of the hepatocytes in the liver were of human
origin) (67). CYP1A1/2 and CYP3A4 mRNA, protein
content, and enzyme activity have been shown to be induced
in chimeric mice treated with known human inducers and in
hepatocytes isolated from humanized chimeric mice (68–70).
In Vivo Monkey
Rhesus and cynomolgus monkeys are used routinely for
preclinical pharmacological, pharmacokinetic and safety eval-
uations and more recently for evaluations of in vivo drug
interactions. The recent cloning of rhesus monkey CYP3A64
revealed 93% homology in the protein sequence with human
CYP3A4 and 83% homology to CYP3A5 (71). More
importantly, the nucleotide sequences of ligand binding
domains between rhesus and human PXR are 96% similar
(11). In vitro studies using monkey hepatocytes showed that
rifampicin induced CYP3A64 mRNA with an EC50=0.5 μM
(72), which is similar (EC50=0.2 μM) to that reported for
human hepatocytes (28). In rhesus monkeys, the pharmaco-
kinetics of midazolam can be signiﬁcantly altered with
rifampicin co-administration, resulting in reduced systemic
exposure and hepatic bioavailability (72), similar to human.
The ability to employ an in vivo animal model that replicates
human pharmacokinetic changes would be extremely useful
in placing in vitro results in the proper context and the
similarities between human and monkey suggest that
monkeys have the potential to be a predictive tool for human
CYP3A-mediated drug interactions.
CHALLENGES AND SUMMARY
One of the biggest challenges in predicting human DDIs
from in vitro experiments is the lack of understanding
between in vitro drug concentrations and drug concentration
at the site of action in the liver. This is complicated by several
factors, such as, protein binding or non-speciﬁc binding in
vitro and in vivo, the use of total vs. free (unbound)
efﬁcacious plasma concentrations, or the use of systemic vs.
portal vein drug concentrations, and compounds with low or
high liver-to-plasma ratios. The two most common
approaches in all human in vitro models are: (1) total
efﬁcacious systemic Cmax or Css concentration or (2) unbound
drug concentration at the portal vein (18,21,22). The former
approach does not account for protein binding effects on drug
disposition, yet is considered a conservative estimate that uses
a high (total) drug concentration after the ﬁrst-pass effect
(metabolism/elimination). The latter approach does account
for protein binding on drug disposition and reﬂects the
maximum drug absorbed and presented to the liver.
Extrapolations from in vitro induction studies are chal-
lenging when the compound being evaluated is also an
inhibitor of CYP enzymes. If the compound is an inhibitor,
enzyme induction can be missed when only activity is
assessed. For example, CI-1034 (endothelin-A antagonist) is
an inducer and metabolism-based inhibitor of CYP3A4 and
activity assays revealed no change in enzyme activity (73).
Due to the common nature of CYP inhibition, conducting
both activity and mRNA analysis are encouraged. Also, when
utilizing data on only CYP1A1/2 and CYP3A4 induction, it is
possible to under-predict clinical induction. This can also be
due to the cross talk between the nuclear receptors e.g. PXR
and CAR (74). When evaluating only CYP1A and CYP3A
and not CYP2B6, induction via CAR could be misrepre-
sented. Finally, cytotoxicity assessments should be conducted
with cell-based systems to ensure that a negative response is
not due to cell death. Often this can be as simple as
visualizing the cells under a microscope and observing cell
morphology up to and including more sophisticated measures
of cell membrane permeability or cell death.
Figure 3 illustrates the possible models that can be
employed while assessing the CYP induction potential of new
drug candidates. From HTS models, which mimic the early
steps of the enzyme induction process and have utility in
SAR, mechanistic, and prediction, to intermediate assays
which incorporate larger numbers of CYP enzymes and their
respective induction pathways. Moving eventually to primary
human hepatocytes and ultimately to clinical DDI studies
where actual effects on pharmacokinetic parameters of co-
administered drugs (or inducing agent itself/autoinduction)
are measured and subsequent dosing guidelines are adopted.
While all of the assays provide useful SAR, mechanistic or
conﬁrmatory information pertaining to potential enzyme
induction, the most useful and accepted model remains
primary human hepatocytes.
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